期刊文献+

胰液K-ras12密码子点突变联合胰液CA19-9水平与胰腺癌的复发关系 被引量:2

Observation on the Relationship between K-ras Mutation in Pancreatic Juice Accompanying by CA19-9 Level and Recurrence of Pancreatic Carcinoma
下载PDF
导出
摘要 目的:探讨胰液中K-ras12基因密码子点突变和胰液CA19-9水平与胰腺癌术后复发的关系。方法:采用内镜ERCP从胰管收集的胰液标本,测定48例临床及手术证实的胰腺癌患者胰液CA19-9水平,并采用聚合酶链反应-限制性片断长度多态性分析(PCR-RFLP)检测胰液K-ras基因12密码子点突变,分析K-ras12密码子点突变及胰液CA19-9水平与胰腺癌术后复发的关系。结果:(1)胰液中K-ras12密码子点突变率为54.17%,与肿瘤大小密切相关(P<0.05)。K-ras12密码子点突变阳性、阴性表达病例3年复发率分别为61.90%和38.10%。(2)胰液CA19-9高水平且K-ras12密码子点突变阳性组3年复发率为62.5%,而胰液CA19-9低水平且K-ras12密码子点突变阳性组3年复发率为30.0%,两者有显著差异检测(P<0.05)。结论:联合胰液中K-ras12密码子点突变和胰液CA19-9水平可作为判断胰腺癌术后复发的有效指标,多因素分析对判断胰腺癌术后复发更有价值。 Objective:To study the relationship between K-ras mutation in pancreatic juice accompanying by CA19-9 level and recurrence of pancreatic carcinoma.Methods:K-ras point mutation was detected using the polymerase chain reaction and restriction fragment-length polymorphism(PCR-RFLP) in pure pancreatic juice(PPJ),which were collected from the pancreatic togarphy(ERCP).And CA19-9 levels were examined in 32 patients with pancreatic carcinoma.The relationships between K-ras and CA19-9 level and recurrence rate were analyzed.Results:(l) The positivity of K-ras point mutation in PPJ was 54.17%,the positivity of K-ras point mutation in PPJ correlated with tumor recurrence rate(P〈0.05).(2) The recurrence rate in high CA19-9 level group with positive K-ras point mutation in PPJ was 62.50%,while in hypo CA19-9 level was 30.0%,(P〈0.05).Conclusion:K-ras mutation in pancreatic juice and CA19-9 level are effective in dictators for recurrence and prognosis of pancreatic carcinoma.The analysis of multi-gene is more valuable than that of single.
出处 《中国临床医学》 北大核心 2008年第3期358-359,共2页 Chinese Journal of Clinical Medicine
关键词 K-RAS 基因 胰液 CA19-9 胰腺癌 K-ras Gene Pancreatic juice CA19-9 Pancreatic carcinoma
  • 相关文献

参考文献2

  • 1LuttgesJ, SchLehe B, Menke M A, et al. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium[J]. Cancer, 1999, 85 (8):1003-1010.
  • 2Kindo H, Sugnon K, Fukayama N, et al. Detection of point mutation in K-ras oncongene at colon 12 in pure pancreatic juice for diagnosis of pancreatic cancer[J] . Cancer, 1992, 80: 568-746.

同被引文献10

  • 1Jemal A,Murray T,Ward E,et al. Cancer statistics[J].2005,CA Cancer J Clin,2005,55 : 10-30.
  • 2Niederau C,Grendell JH. Diagnosis of pancreatic cancer. Ima ging studies and tumor markers[J]. Pancreas, 1992,7(10):66 -86.
  • 3DiMagno EP,Reber HA,Tempuro MA. AGA technical review on epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association[J]. Gastroenterology, 1999,117 : 1464-1484.
  • 4Pasanen PA, Eskelinen M, Partanen K, et at. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA,CA50 and CA242 in pancreatic cancer,results from a prospective study [J].Br J Cancer, 1993.67(4).852- 855.
  • 5Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA242 with CA19 9 and carcinoernbryonic antigen (CEA) in pancreatic cancer [J]. Hepatogastroenterology, 2003,50 ( 53 ) :1669 -1674.
  • 6Diane MS,Baoan JI,Mousumi B,et al. CEACAM1 ,a Novel Serum biomarker for pancreatic cancer[J].Pancreas, 2007,4( 34): 436-444.
  • 7王建承,费健,顾志冬,张卓,陈胜,邓漾,朱坚,吴卫泽,彭承宏,李宏为.胰腺癌患者不同体液中CA19-9检测及其临床意义[J].诊断学理论与实践,2007,6(5):438-440. 被引量:1
  • 8梁雪,聂桓,李钰.胰腺癌早期诊断肿瘤标志物的研究进展[J].实用肿瘤杂志,2011,26(4):422-426. 被引量:2
  • 9傅德良,倪泉兴.胰腺癌的早期诊断和治疗进展[J].中国临床医学杂志,2000,7(1):107-109. 被引量:4
  • 10邓登豪,朱海杭,吴岩,颜万顺.胰腺癌肿瘤标志物单项和联合检测的价值[J].胃肠病学和肝病学杂志,2001,10(1):60-62. 被引量:13

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部